(Q44317928)

1 December 2017

title

Response to alendronate in osteoporotic women previously treated with pamidronate (English)

1 reference

1 December 2017

0 references

5

Serge Rozenberg

1 reference

1 December 2017

Anne Peretz

1

1 reference

1 December 2017

Vania Siderova

2

1 reference

1 December 2017

Jean Jacques Body

3

1 reference

1 December 2017

Jean Claude Dumon

4

1 reference

1 December 2017

Caroline Fellemans

6

1 reference

1 December 2017

Michel Fuss

7

1 reference

1 December 2017

Pierre Bergmann

8

1 reference

1 December 2017

Interdisciplinary Group for the Study of Bone Diseases and Calcium metabolism (GIPOB)

9

1 reference

1 December 2017

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

44

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

111-115

1 reference

Treatment of osteoporosis with bisphosphonates

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Dosing regimens and main adverse events of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Response to alendronate in osteoporosis after previous treatment with etidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Adverse effects of bisphosphonates. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Cyclical pamidronate infusions in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

Changes in bone remodeling rate influence the degree of mineralization of bone which is a determinant of bone strength: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2802%2900318-3

7 January 2021

10.1016/S0378-5122(02)00318-3

Identifiers

DOI

1 reference

1 December 2017

1 reference